2018 Korean Guideline of Atrial Fibrillation Management by �젙蹂댁쁺
1033https://e-kcj.org
ABSTRACT
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general 
population. The Korean Heart Rhythm Society organized a Korean AF Management 
Guideline Committee and analyzed all available studies regarding the management of AF, 
including studies on Korean patients. This guideline is based on recent data of the Korean 
population and the recent guidelines of the European Society of Cardiology, European 
Association for Cardio-Thoracic Surgery, American Heart Association, and Asia Pacific 
Heart Rhythm Society. Expert consensus or guidelines for the optimal management of 
Korean patients with AF were achieved after a systematic review with intensive discussion. 
This article provides general principles for appropriate risk stratification and selection of 
anticoagulation therapy in Korean patients with AF. This guideline deals with optimal stroke 
prevention, screening, rate and rhythm control, risk factor management, and integrated 
management of AF.
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PREAMBLE
This guideline is based on recent data of the Korean population and the recent guidelines.1-5) 
The level of evidence and strength of the recommendation of particular management options 
were weighed and graded according to predefined scales as outlined in Tables 1 and 2. The 
Korea Heart Rhythm Society (KHRS) Committee for Practice Guidelines supervises and 
coordinates the preparation of a new guideline produced by task forces, expert groups, or 
consensus panels. The Committee is also responsible for endorsing this guideline.
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INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general 
population.6-9) AF increases the risk of mortality and morbidity resulting from stroke, 
congestive heart failure (HF), and impaired quality of life, explaining its enormous 
socioeconomic and healthcare implications.10) The prevalence of AF has been projected to 
increase to 12 million people in the USA by the year 2050 and 17.9 million in Europe by the 
year 2060, with more than half of these patients being ≥80 years of age, leading to substantial 
public health and economic burdens.11-13) Consequently, the healthcare burden associated 
with AF is growing considerably and is mainly driven by hospitalizations.14)15) As populations 
continue to age, AF is likely to become a greater public health burden.
EPIDEMIOLOGY OF ATRIAL FIBRILLATION IN KOREA
Many of the risk factors for developing AF also lead to complications related to AF such 
as stroke and death. The prediction of incident AF has been the focus of reviews, and risk 
factors have been used to derive clinical risk scores for incident AF.16)17) The largest derivation 
and validation in an Asian population (including Korea) is the simple C2HEST score: C2: 
coronary artery disease (CAD)/chronic obstructive pulmonary disease (COPD) (1 point each); 
H: Hypertension; E: Elderly (Age ≥75, doubled); S: Systolic HF (doubled); T: Thyroid disease 
(hyperthyroidism).18)
Prevalence and incidence of atrial fibrillation
Reliable prevalence and incidence figures are needed for clinicians and policymakers.19) 
The prevalence of AF progressively increased by 2.10-fold from 0.73% in 2006 to 1.53% 
in 2015 in Korea. The prevalence was significantly greater in men than in women for all 
years (Figure 1A). The annual trends of AF incidence were stable with the 10-year overall 
incidence of 1.77 per 1,000 person-years. The 10-year overall incidence in men was 1.89 per 
1,000 person-years, 1.16 times higher than 1.65 per 1,000 person-years in women, and the 
tendency was consistent over the study period (Figure 1B).20) The prevalence of AF in Korea 
was similar to the recent prevalence rates of 1.07–1.6% in Asia; 1.07% in 2011 in Taiwan,21) 
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Table 1. Recommendation classes
Classes of 
recommendations Definition Suggested wording to use
Class I Evidence and/or general agreement that a given treatment or 
procedure is beneficial, useful, effective.
Is recommended/ 
is indicated
Class II Conflicting evidence and/or a divergence of opinion about the 
usefulness/efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered
Class III Evidence or general agreement that the given treatment or procedure 
is not useful/effective, and in some cases may be harmful.
Is not recommended
Table 2. Levels of evidence
Levels of evidence Definition
Evidence A Data derived from multiple RCTs or meta-analyses.
Evidence B Data derived from a single RCT or large non-randomized studies.
Evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries.
RCT = randomized controlled trial.
1.5% in Singapore,22) and 1.6% in 2006 in Japan.23) Across all age groups, the prevalence 
consistently increased over the study period, except the prevalence among those aged 20–29 
years decreased significantly (Figure 2A). The annual AF incidence in subjects aged ≥80 years 
increased significantly from 12.1 in 2006 to 14.3 per 1,000 person-years in 2015, while the 
incidences in all other age groups decreased (Figure 2B).20) Patients with regular hospital 
visits showed a lower prevalence of AF and an increasing trend of the incidence of AF.24)25)
The prevalence of Korean AF is expected to be 5.81% (2,290,591 AF patients) in 2060 (Figure 3), 
while the prevalence of Taiwan AF is estimated to be 4.01% in 2050.21) Although the prevalence 
of AF is increasing steeply in Asia, it remains lower in Korea (and many Asian countries) than 
that of Western populations. Because AF is becoming an important public health burden, 
regional and socioeconomic inequality of AF patterns and treatment is also important.26) The 
prevalence of AF differs according to geographical regions and income levels.27)
The proportion of patients with a congestive HF, hypertension, age ≥75 (doubled), diabetes 
mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65–74, 
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Figure 1. Annual prevalence (A) and incidence (B) of AF, 2006–2015, stratified by sex. 
AF = atrial fibrillation. 
*p value for increasing trends <0.001. †p value for decreasing trends <0.001.
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Figure 2. Annual incidence (A) and prevalence (B) of AF, 2006–2015, stratified by age. 
AF = atrial fibrillation. 
*p value for increasing trends <0.001. †p value for decreasing trends <0.001.
female (CHA2DS2-VASc) score ≥2 increased from 68.8% to 81.2% from 2006 to 2015. The 
proportion of patients with high bleeding risk according to HAS-BLED (hypertension, 
abnormal renal/liver function [1 point each], stroke, bleeding history or predisposition, labile 
international normalized ratio [INR], elderly [0.65], drugs/alcohol concomitantly [1 point 
each]) (score ≥3) increased from 39.3% in 2006 to 59.1% in 2015 (Figure 4).20)
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Figure 4. Temporal trends of newly diagnosed AF patient by CHA2DS2-VASc and HAS-BLED scores, 2006–2015. 
AF = atrial fibrillation.
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Figure 3. The projected prevalence of atrial fibrillation.
Hospital care burden of atrial fibrillation
Overall, hospitalizations for AF increased by 420% from 767 to 3,986 per 1 million Korean 
population from 2006 to 2015. Most admissions occurred in patients aged ≥70 years, and 
the most frequent coexisting conditions were hypertension, HF, and COPD. Hospitalizations 
mainly due to major bleeding and AF control increased, whereas those mainly due to 
ischemic stroke and myocardial infarction decreased.8)28)
The total cost of care increased even after adjustment for inflation from ₩8.79 billion (€68.4 
million) in 2006 to ₩49.8 billion (€388.4 million) in 2015, equivalent to 0.78% of the Korean 
National Health Insurance Service (NHIS) total expenditure (Figure 5). The total care cost 
related with AF was estimated as $16–26 billion in the United States, accounting for 1% of the 
national healthcare budget in the United Kingdom.15)29)30)
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Figure 5. Temporal trends of medical costs, 2006–2015. (A) Korean NHIS total expenditures (million €), (B) total AF hospitalization costs (million €), and (C) the 
proportion of total AF hospitalization costs to Korean NHIS total expenditures (%). 
AF = atrial fibrillation; NHIS = National Health Insurance Service. 
*p value for trends <0.001.
Prognosis of atrial fibrillation
Among prevalent AF patients, annual event rates for all-cause mortality, ischemic stroke, 
intracranial bleeding, HF admission, and myocardial infarction significantly declined for 
a decade. In contrast, these events did not change among the non-AF Korean population 
(Figure 6). Over the last 5 decades, AF-associated mortality decreased by 25% in the 
Framingham Heart Study.31)
In Korea, we observed a 20% reduction in mortality over a decade from 5.0%/year in 2006 
to 4.0%/year in 2015.20) Overall in-hospital mortality decreased from 7.5% in 2006 to 
4.3% in 2015.28) The in-hospital mortality was highest in patients ≥80 years of age (7.7%) 
and in those with chronic kidney disease (7.4%). Improved survival after AF onset may 
arise from: 1) earlier detection (lead time) owing to heightened awareness; 2) changed 
diagnostic criteria (as described above); 3) enhanced surveillance of AF patients; 4) 
advances in guideline-recommended treatments for AF32) including oral anticoagulation 
(OAC) therapy to reduce the risk of embolization3); and 5) more aggressive treatment of 
complications and comorbidities such as hypertension, ischemic heart disease, HF, and 
hypercholesterolemia.18
Given the high mortality associated with HF33) and stroke,34) the 52% reduction in HF 
subsequent to AF observed over the study period and the 9% reduction in risk of ischemic 
stroke is likely to have contributed substantially to the improved survival. Although our 
results showing a declining associated risk for HF and stroke following AF are in line with 
those for other Western populations,31) the 1-year rates of HF and stroke are 0.2%/year and 
1.8%/year, which are still higher than 0.1%/year and 0.6%/year in an age- and sex-matched 
non-AF population in 2013.
SCREENING FOR ATRIAL FIBRILLATION
The early detection of asymptomatic AF could prevent associated ischemic stroke associated 
by instituting appropriate anticoagulation.35)36) AF first diagnosed at the event of stroke 
comprise nearly 10% of total ischemic stroke cases. The incidence of screen-detected AF 
strongly depends on the population screened and screening duration/intensity.37)
1038https://e-kcj.org https://doi.org/10.4070/kcj.2018.0339
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Figure 6. Temporal trends in 1-year adverse event rates of prevalent AF Korean population each year. 
AF = atrial fibrillation; HF = heart failure 
*p value for trends <0.001.
Screening for atrial fibrillation by 12-lead electrocardiography
To diagnose AF, its documentation on electrocardiogram (ECG) is mandatory. As the 
misdiagnosis of AF could cause unnecessary risks and costs for patient management, 
confirming the diagnosis on ECG is essential. The American College of Cardiology/
American Heart Association/Heart Rhythm Society guideline of the management of AF 
recommends the ECG documentation of AF as a class I indication.2) Moreover, AF is 
frequently asymptomatic, especially in older people.38) As such, symptom-driven ECG has 
a substantial limitation for detecting AF. One study revealed that 161 of 476 individuals 
with new subclinical AF were at an increased risk of cardiovascular and all-cause mortality 
compared to patients with typical symptoms after the adjustment for age and stroke risk 
score.39) Another study showed that a single-point screening of a general population ≥ 65 
years of age detects subclinical AF in 1.4% of cases and that AF is almost always persistent.40) 
In the prospective EURObservational Research Programme registry, mortality at 1 year 
was more than 2-fold higher in asymptomatic than symptomatic patients (9.4% vs. 4.2%, 
p<0.001) independent of age and comorbidities.41) In the Belgrade AF study including 
consecutive first-diagnosed AF patients, 10-year survival free of ischemic stroke or AF 
progression was worse in patients with an asymptomatic presentation.42) The SAFE study43) 
showed that targeted and total population screening for subclinical AF seems cost-effective 
in people aged ≥65 years, and similar results were repeatedly reported using intermittent 
ECG screening in different populations.44)45) A systemic review showed screening of elderly 
people revealed a prevalence of 2.3% for persistent AF using short-term ECG monitoring or 
ECG after pulse palpation.40) These findings encourage the further evaluation of systematic 
AF screening programs in elderly or increased risk populations, such as stoke survivors or 
patients with intracardiac devices.
Extended-term screening for atrial fibrillation
As elderly populations continue increasing, the incidence of subclinical AF is also 
increasing.46) Furthermore, due to recent advances in new technologies, underdiagnosed 
AF could be detected. Stepwise screening with 12-lead ECG and handheld ECG recordings 
increased the rate of diagnosis of asymptomatic paroxysmal AF in unselected residents of 
Halmstad, Sweden aged 75–76 years.47) Long-term monitoring with implantable or wearable 
devices like smartphones or smart watches has been validated for the detection of short-term 
asymptomatic AF.
In the REHEARSE-AF study, self-screening using a handheld ECG device once or twice weekly 
demonstrated a hazard ratio of 3.9 for the detection of AF at 12 months compared with 
routine care.48) A nongovernmental organization–led community-based screening program 
based around community centers demonstrated that the prevalence of AF was 2.3% and 
newly diagnosed AF was 0.69% with a mean CHA2DS2-VASc score of 3.9±1.5.49) The ASSERT-
II study investigated the prevalence of subclinical AF among 256 patients with an average 
left atrial volume of 76.5 mL using implantable loop recorders, and subclinical AF lasting 
≥ 5 minutes was detected among 34.4% of patients per year over a mean follow-up of 16 
months.50) From these data, the AF-SCREEN group, an international collaboration including 
more than 100 physicians, nurses, allied health professionals, health economists, and patient 
advocates, endorsed the use of routine screening of at-risk populations.35)
Screening of patients with intracardiac device or previous stroke
A cardiac-implanted electronic device (CIED) could continuously monitor atrial rhythm and 
detect atrial high-rate episodes (AHRE). However, AHRE has been not used to detect AF. A 
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minimum 5-minute AHRE duration had clinical relevance in the MOST study.51) Alternative 
arbitrary or data-derived AHRE burden cut points ranging from 5 minutes to 24 hours have 
been explored over the subsequent 10 years.52) The ASSERT study indicated that stroke risk 
was increased only in patients with AHRE ≥24 hours.53) The stroke risk in AHRE patients 
seemed lower than that in patients with diagnosed AF,54) and strokes often occur without 
AHRE being detected within 30 days before the event.55-58) Patients with CIED should be 
regularly screened for AHRE, while those with AHRE should undergo further assessments for 
stroke risk factors and overt AF, including ECG monitoring.
Stroke is the first manifestation of AF in >25% of AF-related stroke cases.59) In the Swedish 
registry of ischemic strokes, approximately 9% were associated with subclinical AF and 
20% with undertreated AF,59)60) whereas in a global registry, 10% were caused by previously 
unknown AF.61) Sequential ECG monitoring detected AF in 23.7% of stroke survivors62) and 
in 11.5% in different meta-analyses of prospective observational studies or randomized 
controlled trials (RCTs),50) with variations depending on optimal timing, methods, and 
duration of monitoring for the detection of AF. Cryptogenic stroke defined as the cause 
of ischemic stroke remains uncertain despite a complete diagnostic evaluation.63) AF 
detection is not uncommon in unselected stroke patients (hazard ratio [HR], 6.2; 95% 
confidence interval [CI], 4.4–8.3),64) but is more likely in patients with cryptogenic stroke 
with implantable loop recorders or who have undergone prolonged ECG monitoring.64)65) 
Accordingly, prolonged ECG monitoring seems reasonable in all survivors of ischemic stroke 
without overt AF.
Summary of recommendations for AF screening
DETECTION AND MANAGEMENT OF RISK FACTORS AND 
CONCOMITANT CARDIOVASCULAR DISEASE
Several concomitant conditions are closely related to AF development, recurrence, 
and complications. The prevention, detection, and treatment of these conditions are 
essential to preventing AF and reducing its burden. AF independently increases all-
cause mortality, and only 1 in 10 deaths in AF patient are related to stroke, while >7 in 
10 are cardiovascular.66) Hence, cardiovascular and comorbidity risk management is 
essential as part of the holistic or integrated care of AF management to reduce deaths and 
hospitalisations.66)
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Recommendations Class Level
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in 
patients >65 years of age.
I B
In patients with transient ischemic attack (TIA) or ischemic stroke, screening for AF is 
recommended by short-term ECG recording followed by continuous ECG monitoring for at 
least 72 hours.
I B
It is recommended to interrogate pacemakers and ICDs on a regular basis for AHRE. In cases 
of AHRE detected by a CIED of at least 5 minutes duration, we suggest that direct analysis 
of electrograms corresponding to AHRE is clinically indicated to exclude artifacts or other 
causes of inappropriate detection of atrial tachyarrhythmias or AF (ungraded consensus-
based statement).
IIa B
In stroke patients, additional ECG monitoring by long-term noninvasive ECG monitors or 
implanted loop recorders should be considered to document silent atrial fibrillation.
IIa B
Systematic ECG screening may be considered to detect AF in patients aged >75 years, or those 
at high stroke risk.
IIa B
HF and AF coexist in many patients and can exacerbate each other. HF is a risk factor of AF 
(HR, 1.43; 95% CI, 0.85–2.40).67)68) The principal of AF management in HF patients does not 
differ from that in patients without HF, and these efforts should be performed regardless of 
left ventricular ejection fraction (LVEF).69) Appropriate OAC therapy by patient stroke risk 
is crucial and optimal HF therapy by guideline is also important.69) Angiotensin-converting 
enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) with a beta-blocker or 
eplerenone reduced the risk of new-onset AF in patients with reduced LVEF HF patients.70-74) 
According to recently published data in the CASTLE-AF trial, catheter ablation of AF reduced 
the risk of all-cause death (47%) and cardiovascular death (51%) in patients with HF and 
reduced LVEF.75) Catheter ablation of AF in HF patients could be a treatment option for 
improvement outcomes in selected patients.
Hypertension is a risk factor of AF development (HR, 1.32; 95% CI, 1.08–1.60) and a 
risk factor of stroke and bleeding in AF patients. Good blood pressure control should be 
considered part of the optimal care of AF patients.68)76)77) Several previous reports suggested 
that ACEIs or ARBs had a beneficial effect on new-onset AF and the prevention of AF 
recurrence.70-72)78-82)
Diabetes is a commonly prevalent comorbidity with AF sharing common risk factors.83-86) 
Diabetes is a risk factor of AF (HR, 1.25; 95% CI, 0.98–1.60) and a risk factor of stroke in AF 
patients, with no profound differences between type I and type II diabetes.68)87)88) Although 
there is no evidence that intensive glycemic control does not reduce AF development, 
diabetes severity is associated with an increased risk of AF development (e.g. diabetic 
retinopathy).87)89)
INTEGRATED TREATMENTS FOR ATRIAL FIBRILLATION 
PATIENTS
One important issue for implementing integrated care management of AF is how to get 
people to remember the components of such an approach. The latter should streamline the 
holistic management pathway whether in primary care, hospitals and even understanding 
by patient.
Use of the ABC pathway of integrated care management is suggested as follows: 1) ‘A’ 
Avoid stroke with Anticoagulation; 2) ‘B’ Better symptom management (i.e. patient-
centered, symptom directed decisions on rate vs. rhythm control); 3) ‘C’ Cardiovascular and 
comorbidity management, including lifestyle factors (Figure 7).90) Application of the simple 
ABC pathway allows the streamlining of integrated care for AF patients in a holistic manner 
and has been reported to be associated with a lower risk of adverse outcomes, including 
recent data in a Korean cohort.66) An integrated approach for AF management is the basis 
of consistent guideline-based treatment of AF and such guideline adherence helps improve 
patient outcomes.91-94)
To accurately assess the effect of AF on cardiovascular disease, it is necessary to refer to a 
cardiologist after an initial diagnosis, especially if acute treatment is required, as follows: 
1) unstable vital signs including uncontrollably fast heart rate; 2) symptomatic bradycardia 
despite reduction or stopping of nodal blocker; 3) ongoing or severe angina with reduced left 
ventricular function; and 4) transient ischemic attack, stroke, or thromboembolic events.
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Components of integrated care
Integrated AF care include patient's active participation, multidisciplinary approach 
technology use, and all treatment approach (Table 3).
Active patient participation
Chronic diseases such as AF can be expected to have a better long-term therapeutic effect 
if the patient is well aware of the disease and his or her responsibility in the treatment 
process.95) Patient-oriented treatment, including the involvement of patients in the decision-
making stage, can increase compliance and respect individual preferences, requirements, 
and autonomy.96) However, the awareness rate of AF was <10% in 2017, which was conducted 
by the KHRS (release in press conference). Therefore, the KHRS is making diverse efforts 
to increase awareness of the general public through information campaigns, including 
risk factor information, recognition, treatment, and self-management of the disease. 
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The ABC pathway for integrated care management
‘A’ Avoid stroke 
optimize stroke
prevention
‘Birmingham 3-step’ Step 1· Identify low risk patients
Step 2
· Offer stroke prevention to patients with         
one or more risk factors for stroke
· Assess bleeding risk
Step 3
· Decide on OAC (either a VKA with 
well-managed TTR or NOAC)
Patient-centered and symptom-directed
decisions on rate or rhythm control
· Manage hypertension, heart failure, diabetes 
mellitus, cardiac ischemia, and sleep apnea
· Lifestyle changes: obesity reduction, regular 
exercise, and reduction of alcohol and
stimulant use
· Patient psychological morbidity
· Consider patient values and preferences
‘B’ Better symptom
management
treat symptoms
‘C’ Cardiovascular and
other comorbidities
manage risk factors
Figure 7. The basic concept of acute and chronic management of AF. Modified from Lip et al.5) 
AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation therapy; TTR = time in therapeutic range.
Table 3. Integrated AF treatment
Patient's active participation Multidisciplinary approach Technology use All treatment approach
• Patients oriented treatment •  Physicians (primary care physicians, 
cardiologists, cardiovascular surgeons, 
arrhythmia specialists, and stroke 
specialists) and allied health professionals
•  Technical support for free 
communication among team 
members
• Life style modification
• Patient education by specialists •  Good communication and education 
between the patient and the physician
•  Checklist and communication 
tools
• Anticoagulation
•  Encouragement for autonomy,  
self-management
•  Monitoring tool on therapy 
adherence and effectiveness
• Rate control
•  Proper control on related 
comorbidities
• Rhythm control by AADs
•  Patient's active participation on 
decision marking
•  Catheter ablation and surgical interventions 
(ablation, LAA occluder, AF surgery, etc.)
AAD = antiarrhythmic drug; AF = atrial fibrillation; LAA = left atrial appendage.
Self-management includes adapting to the treatment process, changing lifestyles, such as 
smoking cessation and weight control, and requires patients to be aware of the treatment 
method and goal.97)98)
Multidisciplinary approach
A multidisciplinary approach involving primary care physicians, cardiologists, cardiovascular 
surgeons, arrhythmia specialists, and stroke specialists who first encounter the patient 
can help the patient actively participate in treatment. By engaging the patient in the 
stage, the patient can adhere to the treatment, which enhances its effect.99)100) Thus, a 
multidisciplinary approach to AF involves not only specialized medical knowledge but also 
good communication and education between the patient and physician.
Technological use for smooth communication among medical staff
For the integrated treatment of AF, it is essential to communicate and exchange smoothly 
among members. This requires technical support for free communication between patients 
and physicians, primary care physicians, and arrhythmia specialists. Digital programs and 
smartphone apps can help with this process.101) One pilot study using a smartphone App 
shows how this can be operationalized.102) Because Korea has high rate of smartphone use, a 
smartphone App can potentially be used for the management of AF.
All treatments for atrial fibrillation
The ABC pathway described above includes proactive assessment and management of 
cardiovascular disease and risk factors (cardiovascular and comorbidity risk reduction).90) 
To this end, the active management of related diseases such as obesity, hypertension, 
sleep apnea and diabetes should be performed, and lifestyle corrections such as smoking, 
drinking, and exercise should be corrected.90)103)104)
Diagnostic approach to atrial fibrillation
Integrated assessment of patients with atrial fibrillation
A review of the history of systemic embolism including cardiac infarction and symptoms of AF 
and causes should be performed. The possible causes of correction should be assessed through 
interviews regarding lifestyle habits such as diabetes, hypertension, COPD, obesity, and 
sleep apnea; underlying diseases such as hyperthyroidism; and drinking or smoking.103-110) An 
analysis of standardized Korean NHIS screening data showed that increased blood pressure and 
fasting blood sugar alone increased the incidence of AF in pre-hypertensive and pre-diabetic 
patients.103) Even in an analysis of Asian patients with relatively low degree of body mass index, 
the incidence of AF increased and the prognosis was poor when obesity was comorbid.104)111) 
A 12-lead ECG should be used to evaluate the presence of cardiac conduction disturbances, 
ischemic heart disease, and structural heart disease. Transthoracic echocardiography should be 
performed on all patients to determine the treatment strategy for AF.
Additional diagnostic methods for patients with atrial fibrillation
Twenty-four-hour Holter monitoring is useful for evaluating heart rate and the relationship 
between symptoms and AF. In particular, information about heart rate during exercise or 
activity provided by 24-hour Holter monitoring can be used to determine if the goal of heart 
rate modulation through drug therapy has been achieved. Transesophageal echocardiography 
(TEE) is useful for evaluating left atrial function and screening for thrombus in the left 
atrium. Therefore, the evaluation of intracardiac thrombi through TEE is essential in patients 
who are undergoing invasive sinus rhythm conversion or radiofrequency ablation.112)113)
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Follow-up of patients with atrial fibrillation
Most AF patients require periodic follow-up for continuous optimal treatment. Follow-up can 
be performed by primary care physicians, cardiologists, or arrhythmia specialists. Follow-up of 
the treatment plan, continued patient participation, and any needed treatment modifications 
are necessary. The treatment of AF involves prognosis-related treatment (anticoagulant 
therapy and treatment of cardiovascular disease) and symptom-related treatment (heart rate 
or cardiac rhythm control).90)114) In addition, if AF is partially recurrent, if the overall frequency, 
duration of AF decrease, and clinical symptoms are controlled, it is considered successful. The 
management of diseases (obesity, hypertension, HF, diabetes mellitus, sleep apnea) related to 
AF should be provided continuously,103)106)111)115)116) while lifestyle factors such as smoking and 
drinking should be monitored in an integrated manner.117)118)
STROKE PREVENTION THERAPY IN ATRIAL 
FIBRILLATION PATIENTS
Prediction of stroke risk
Stroke prevention is the principal management priority in patients with AF. Compared to 
control or placebo, OAC therapy reduces the risk of stroke by 64% and the risk of death 
by 26%119) but also increases bleeding risk, which can be fatal. As non-vitamin K oral 
anticoagulants (NOAC) showed improved efficacy and safety compared with warfarin, the 
threshold for initiating OAC therapy decreased from an annual stroke rate of 1.7% with 
vitamin K antagonists to 0.9% with NOAC.120)
The CHA2DS2-VASc score is now used in most guidelines for stroke prevention in patients 
with AF.2)3)121) The adjusted incidence rates (per 100 person-years) of ischemic stroke were 3.79 
in Korea, being 0.26 in low-risk patients (CHA2DS2-VASc score 0 [male] or 1 [female]), 1.18 
in intermediate-risk patients (CHA2DS2-VASc score 1 [male]), and 5.30 in high-risk patients 
(CHA2DS2-VASc ≥2). The incidence rates of patients with a CHA2DS2-VASc score of 1 (male), 2, 
3, 4, 5, 6, and 7 or more were 1.04, 1.91, 2.54, 4.72, 5.79, 8.36, and 8.82, respectively (Table 4).9)
The more recent focus of stroke prevention in patients with non-valvular AF has shifted away 
from predicting “high-risk” patients toward initially identifying patients at a “truly low risk” 
of ischemic stroke in whom OAC has no net clinical benefit.122-125) Korean patients who were 
categorized as “low risk” by the CHA2DS2-VASc score (i.e. score 0 in males or 1 in females) 
consistently had an event rate of <1%/year.9) CHA2DS2-VASc had the best sensitivity (98.8% vs. 
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Table 4. Ischemic stroke or composite thromboembolism endpoint/100 years at risk in relation to CHA2DS2-VASc scores in Korean patients without 
anticoagulation throughout follow-up4)
CHA2DS2-VASc score Number of patients
Ischemic stroke Ischemic stroke/systemic embolism
Unadjusted Adjusted for aspirin* Unadjusted Adjusted for aspirin*
0 (male) or 1 (female) 860 0.23 0.26 0.26 0.29
1 (male) 550 1.04 1.18 1.20 1.35
2 975 1.91 2.21 2.04 2.35
3 911 2.54 2.88 2.67 3.04
4 836 4.72 5.34 5.10 5.76
5 770 5.79 6.54 5.98 6.76
6 513 8.36 9.50 8.61 9.77
7 or more 440 8.82 9.97 9.03 10.21
Total 5,855 3.32 3.79 3.49 3.98
TE = thromboembolic event.
*Adjustment made for exposure to aspirin treatment, assuming that aspirin provides a 19% reduction in TE risk, to give an indication of ‘untreated’ rates.
85.7% in CHADS2 and 74.8% in the ATRIA study) and negative predictive value (98.8% vs. 95.3% 
for CHADS2 and 93.7% for the ATRIA study) for the prediction of stroke incidence and was best 
for predicting the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4; 95% 
CI, 8.8–30.8).125) However, the CHA2DS2-VASc score had lower net reclassification improvement 
and c-index suggesting that it is specifically better to discriminate true low-risk AF for stroke.125)126)
Individual stroke risk factors: sex, age, and hypertension
On multivariate analysis, significant associations between CHA2DS2-VASc risk factors and 
ischemic stroke were observed. The significance of vascular disease or diabetes mellitus were 
attenuated after multivariate adjustment, and female sex (HR, 0.73; 95% CI, 0.64–0.84) had 
a lower risk of ischemic stroke than male sex in Korean NHIS sample cohort (Table 5).9)126) 
Coronary and peripheral artery disease have been reported to be important independent risks 
for stroke in AF.127)128) Several cohort studies have shown that female sex is a risk factor for 
stroke, although this is dependent on age and the presence of other non-sex risk factors.129-133) 
Recently, female sex was suggested as a risk modifier for stroke in patients with AF, rather 
than a risk factor.134) Several Asian cohort studies from Hong Kong,135) China,136) Taiwan,127) 
and Japan137) have suggested that female sex was not an independent risk factor for ischemic 
stroke, again suggesting some potential ethnic differences in the risk of stroke between 
Asian and non-Asian populations. Consistent with previous Asian studies, female sex was 
not a risk factor for stroke in a Korean cohort; instead, it was associated with a lower stroke 
risk of ischemic stroke than male sex. Other risk factors in our population such as older 
age, previous stroke or TIA history, HF, and hypertension remained independent stroke risk 
factors consistent with findings in western cohorts.9)
Older age is the most important predictor of ischemic stroke in Korean and Taiwan patients 
with AF.138)139) Patients aged 65–74 years without other risk factors showed a significantly 
higher risk of stroke than those with one risk factor other than age. Lowering the current age 
threshold (age ≥65 years) in the CHA2DS2-VASc score to age ≥55 years might be appropriate 
among Asian patients with AF.139) Two recent Korean studies suggested that blood pressure 
should be controlled more strictly in AF patients.77)103)
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Table 5. Associations between baseline factors and ischemic stroke in patients without anticoagulant treatment4)
Ischemic stroke
Number with event Univariable Multivariable
HR 95% CI HR 95% CI
Age (years)
<65 161/2,594 Ref Ref
65–74 320/1,700 3.44 2.84–4.16 2.11 1.73–2.58
>75 338/1,561 4.70 3.90–5.68 3.11 2.51–3.85
Women 385/2,835 0.94 0.82–1.07 0.75 0.63–0.86
Ischemic stroke/TIA 411/1,433 3.81 3.32–4.37 2.58 2.23–2.97
Atherosclerotic disease
Myocardial infarction 139/764 1.49 1.24–1.79 0.97 0.81–1.17
Peripheral arterial disease 113/611 1.45 1.19–1.76 0.95 0.78–1.17
Vascular disease* 221/1,206 1.54 1.32–1.80 0.98 0.84–1.15
HF 380/1,869 2.16 1.88–2.48 1.23 1.06–1.42
Hypertension 750/4,422 4.04 3.16–5.17 1.85 1.43–2.40
Diabetes 216/1,168 1.53 1.31–1.79 1.13 0.96–1.32
ESRD 23/89 2.36 1.56–3.57 2.03 1.33–3.09
COPD 134/673 1.72 1.43–2.07 1.13 0.94–1.37
Aspirin use 505/2,636 1.93 1.68–2.23 1.30 1.12–1.50
CI = confidence interval; COPD = chronic obstructive pulmonary disease; ESRD = end-stage renal disease; HF = heart failure; HR = hazard ratio; TIA = transient 
ischemic attack.
*Vascular disease includes previous myocardial infarction, peripheral arterial disease, or aortic plaque.
Recommended anticoagulation for Korean patients.
The performance of CHA2DS2-VASc score in Korean populations is comparable with that seen 
in Western populations. For patients with AF without valvular heart disease, including those 
with paroxysmal AF, who are at low risk of stroke (e.g., CHA2DS2-VASc score of 0 in males or 1 
in females), we suggest no antithrombotic therapy (class III). The next step is to consider stroke 
prevention (i.e., OAC therapy) for patients with 1 or more non-sex CHA2DS2-VASc stroke risk 
factors. For patients with a single non-sex CHA2DS2-VASc stroke risk factor, we suggest OAC 
rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel (class 
IIa); and for those at high risk of stroke (e.g., CHA2DS2 ≥2 in males or ≥3 in females), we 
recommend OAC rather than no therapy, aspirin, or combination therapy with aspirin and 
clopidogrel (class I) (Figure 8).
Where we recommend or suggest in favor of OAC, we suggest using a NOAC rather than 
adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good 
quality anticoagulation control with a time in therapeutic range (TTR) >70%. Attention 
to modifiable bleeding risk factors (e.g., uncontrolled blood pressure [BP], labile INRs, 
concomitant use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) in an 
anticoagulated patient, alcohol excess) should be made at each patient contact, and the HAS-
BLED score used to assess the risk of bleeding whereby ‘high risk’ patients (score ≥3) should 
be reviewed and followed up more frequently. While NOACs are increasingly the preferred 
option, warfarin is still widely used and the SAMe-TT2R2 score (which has been validated 
even in Asian cohorts)140) can help identify patients less likely to do well on warfarin, so as 
to arrange more frequent INR checks, education and counselling – or to consider a NOAC 
instead of warfarin (Figure 9).5)
Dynamic adjustment of stroke and bleeding risk
Many clinical variables of stroke and bleeding risk score have “dynamic” variation through 
follow-up.141-143) Age increases annually in all patients, and incident hypertension, diabetes 
mellitus, vascular disease, congestive HF, and prior stroke or transient ischemic attack may 
become evident in some patients. These dynamic changes in risk factors may increase the 
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Patients with nonvalvular atrial fibrillation
Calculate CHA2DS2-VASc score*
0 (male) or
1 (female)
1 (male) or
2 (female)
No antithrombotic
treatment (III)
NOAC should be
considered (IIa)
If contraindication for OAC,
consider left atrial appendage
occluder (IIb)
NOAC (I) or
vitamin K antagonist (I)
≥2 (male) or
≥3 (female)
Figure 8. Stroke prevention strategy in patients with AF. 
AF = atrial fibrillation; HF = heart failure; NOAC = non-vitamin K oral anticoagulant; OAC = oral anticoagulation. 
*CHA2DS2-VASs score: a congestive HF, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or 
transient ischemic attack (doubled), vascular disease, age 65–74, female.
CHA2DS2-VASc score, stroke risk category, and absolute ischemic stroke rate. Despite using 
only baseline CHA2DS2-VASc score to predict the risk of ischemic stroke in AF patients, a 
time-dependent CHA2DS2-VASc score and “delta CHA2DS2-VASc score” (follow-up minus 
baseline) improved the prediction of ischemic stroke in Korean and Taiwan AF populations 
(Figure 10).141)142)
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Step 2
Consider stroke
prevention in all
patients with ≥ 1
additional stroke
risk factors
Step 3
Begin NOAC
(or VKA with
high time in
therapeutic range)
NOACs generally
recommended as first line
therapy for OAC
If considering VKA,
calculate SAMe-TT2R2
score
SAMe-TT2R2 score 0–2
VKA treatment (eg. Warfarin)
… or NOAC
SAMe-TT2R2 score > 2 NOAC  
.. Otherwise, regular review/frequent INR
checks/counselling for VKA users
*Address modifiable bleeding risk factors in all AF patients
Calculate the HAS-BLED score*
If HAS-BLED ≥3, address the modifiable bleeding risk factors and
‘flag up’ patients for regular review and follow-up
High bleeding risk scores should not be used as a reason to withhold OAC.
Step 1
Identify low-risk
patients
No antithrombotic
treatment
Low stroke risk
CHA2DS2-VASc score:
0 in males
1 in females
Figure 9. Practical management algorithm in light of the 2018 American College of Chest Physicians guidelines, 
which are evidence based and GRADE. 
AF = atrial fibrillation; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; 
OAC = oral anticoagulation therapy. 
*HAS-BLED: hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, 
labile INR, elderly (0.65), drugs/alcohol concomitantly (1 point each).
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5 year (Baseline-2010)
∆ CHA2DS2-VASc for
Figure 10. Receiver operating characteristic curves of Δ CHA2DS2-VASc score for predicting ischemic stroke during the entire second follow-up period. 
AUC = area under the curve; CI = confidence interval; SE = standard error.
Recommended non-vitamin K oral anticoagulants dose regimen for Korean 
patients
The benefits of NOAC was more profound in Asian population than non-Asian population.144) 
Based on the standard dose group, NOAC was more effective (OR of stroke/systemic 
embolism, 0.65 vs. 0.85; p interaction=0.045) and safer (OR for major bleeding, 0.57 vs. 
0.89; p interaction=0.046) in Asians than non-Asians. Among high-risk Asian AF population, 
dabigatran, rivaroxaban, and apixaban demonstrated similar risk of ischemic stroke and lower 
risk of intracerebral hemorrhage compared with warfarin. All-cause death was significantly 
lower only with dabigatran and apixaban, whereas not with rivaroxaban in a Korean study.145) 
However, rivaroxaban also decreased all-cause death in a different Korean study.146)
Elderly patients with AF (such as those aged ≥80 years) and patients with impaired renal 
function were included in the landmark NOAC trials, but these important subgroups 
comprised only a small proportion of the patient populations. For dabigatran, reduction 
of the daily recommended dose to 110 mg twice daily (b.i.d.) is indicated for patients aged 
≥80 years. This dose can be reduced to 110 mg b.i.d. if the patient is aged 75–79 years and 
has other comorbidities that could affect bleeding risk such as previous gastritis, peptic 
ulcer disease, and moderate renal impairment. Indeed, label (or guideline) – adherent use 
of dabigatran is clearly associated with better outcomes for stroke, major bleeding, and 
mortality.147)148) Insufficient published data for apixaban, edoxaban, and rivaroxaban indicate 
that further work is needed to clarify the bleeding risks of NOAC in the elderly.
For Korean patients with AF, a reduced dosing regimen for dabigatran (110 mg b.i.d.) in 
patients aged ≥75 years or who have an estimated glomerular filtration rate (eGFR) of 30–50 
mL/min; rivaroxaban (15 mg once daily [q.d.]) in patients aged ≥80 years or with an eGFR of 
15–49 mL/min; apixaban (2.5 mg b.i.d.) if 2 of the 3 following criteria are present: age ≥80 
years or an eGFR 15–29 mL/min or body weight ≤60 kg; or edoxaban (30 mg q.d.) if eGFR is 
15–50 mL/min are recommended (Table 6).
Low anticoagulation rate
The OAC rate of total AF in the Korean nationwide cohort remains very low at about 18%, 
while the usage rate of aspirin exceeds 35%.8)25) However, the OAC rate of Korean AF was 
similar to the recent OAC rates of Taiwan nationwide cohort. Li et al.149) reported that the 
overall guideline adherence rate was only 13% and even lower among patients with a high 
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Table 6. Dose reduction of NOACs281)
Drug Dose reduction criteria Dose
Dabigatran Creatinine clearance 30–50 mL/min Dabigatran 110 mg b.i.d.
P-glycoprotein inhibitors*
Clopidogrel, aspirin, NSAIDs
Increased bleeding risk†
Age 75 years or more
Rivaroxaban Age 80 years or more Rivaroxaban 15 mg q.d.
Creatinine clearance 15–50 mL/min‡
Apixaban At least 2: 1) age 80 years or more, 2) body weight 60 kg or less, 3) creatinine ≥1.5 mg/dL Apixaban 2.5 mg b.i.d.
Edoxaban P-glycoprotein inhibitors* Edoxaban 30 mg q.d.
Body weight 60 kg or less
Creatinine clearance 15–50 mL/min‡
b.i.d., bis in die (twice a day or twice daily); NOAC, non-vitamin K antagonist oral anticoagulant; NSAID = nonsteroidal anti-inflammatory drug; q.d., quaque die 
(once a day or once daily).
*P-glycoprotein inhibitors: amiodarone, verapamil, dronedarone, etc.; †Increased bleeding risk: coagulopathy, thrombocytopenia, platelet dysfunction, recent 
major trauma or biopsy, infective endocarditis; ‡Should be used with caution in patients with significant renal impairment (creatinine clearance 15–29 mL/min).
CHA2DS2-VASc score in this non-selected nationwide AF registry. Moreover, guideline-
adherent antithrombotic management was associated with a 38% lower risk of mortality.
The analysis of a prospective multicenter study performed in tertiary hospitals in Korea 
(COmparison study of Drugs for symptom control and complication prEvention of Atrial 
Fibrillation [CODE-AF] registry) showed the optimistic future of stroke prevention in 
patients with AF. The current OAC rate of AF patients with high stroke risk (CHA2DS2-VASc 
score ≥2) was about 83%.150) Consistently, in patients with at least 3-year regular hospital visit, 
OAC prescription rate was higher than nationwide AF registry and tertiary hospital-based 
registry. It was increased from 34.7% to 50.6%, whereas antiplatelet prescription decreased 
gradually from 48.2% to 31.5% between 2008 and 2015.151)
However, the recent improvement of OAC rate in tertiary hospitals in Korea is related with 
increased NOAC use because it was >50%, whereas that of warfarin was still low at 20%. 
Among AF patients with a high stroke risk and at least 3-year regular hospital visits, OAC 
utilization was lower in the suburban/rural regions than that observed in the urban regions 
(48.2% vs. 51.8%, respectively; p<0.001).27)
BLEEDING RISK
Risk factors for bleeding with non-vitamin K antagonist oral anticoagulant, 
vitamin K antagonist, and antiplatelet therapy
Bleeding risk varies from person to person depending on their pre-existing comorbidities, 
current antithrombotic regimen and adherence, concomitant medication, and lifestyle 
choices. Many of these factors cannot be altered but some are modifiable or potentially 
modifiable.5)152)
•  BP control: Good control of BP is vital to reduce the risk of stroke and is essential to decrease 
the risk of bleeding (particularly intracranial haemorrhage) on antithrombotic therapy.
•  Anticoagulation control: Among patients receiving vitamin K antagonist, maintenance 
of an INR in the therapeutic range (2.0–3.0) is essential. The proportion of TTR should 
be at least 65% but the ultimate aim/target should be 100%.
•  Concomitant medication predisposing to bleeding: Nonessential use of concomitant 
antiplatelet drugs and NSAIDs should be avoided since these medications increase the 
risk of bleeding in patients receiving OACs.
•  Alcohol intake: Excessive alcohol intake (chronic or binge drinking) increases the risk of 
bleeding predominantly due to the risk of trauma, but in chronic alcohol abuse through 
poor medication adherence, hepatic and variceal disease.
•  Lifestyle factors: Avoidance of work and/or leisure activities that have the potential to 
cause serious trauma should be advised.
•  Bridging periods off anticoagulation: Interruption of OAC should be avoided to reduce 
stroke risk since the majority of cardiovascular procedures (e.g., pacemaker implantation 
or percutaneous coronary intervention [PCI]) can be safely performed on OAC. 
Bridging (i.e., stopping OAC and providing anticoagulation cover with heparin) should 
be used in patients with mechanical heart valves but does not appear to be otherwise 
advantageous.153)154)
•  Appropriate choice of OAC: Choice of OAC should be made on an individual basis after 
stroke and bleeding risk assessment, discussion with the patient and adherence to the 
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prescribing label.
•  Falls risk and cognitive impairment: The benefits of ischemic stroke reduction generally 
outweigh the risk of harm from serious bleeding with OAC use. One estimate was that 
the patient would need to fall 295 times per year for the risk from falls to outweigh the 
benefits of stroke reduction.155)
•  Reversal of biochemical anomalies: Patients with anemia or reduced platelet count or 
impaired hepatic/renal function should be investigated and proactively managed.
Bleeding risk assessment
Attention to modifiable bleeding risks are important. However, only relying on this to assess 
bleeding risk is an inferior strategy to a formal bleeding assessment score, as shown in 
independent cohorts even from Asia.156-158)
There are multiple bleeding risk scores that have been proposed for bleeding risk 
stratification, with the HEMORR2HAGES (hepatic or renal disease, ethanol abuse, 
malignancy, older, reduced platelet count/function, hypertension, anemia, genetic factors, 
excessive fall risk, and stroke), HAS-BLED (hypertension, abnormal renal/liver function [1 
point each], stroke, bleeding history or predisposition, labile INR, elderly [0.65], drugs/
alcohol concomitantly [1 point each]), ATRIA, ORBIT, and ABC-bleeding scores that have 
been derived and validated in AF populations.159)
The simple HAS-BLED score has been shown to be similar or outperform older bleeding 
scores, as well as more simple bleeding scores that include fewer clinical parameters. A high 
bleeding risk score is not a reason to withhold OAC, as the net clinical benefit is even greater 
in those patients with high bleeding risk.
Recommendations for stroke prevention in patients with AF
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Recommendations Class Level
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients with AF. I A
OAC is recommended for all male AF patients with a CHA2DS2-VASc score ≥2, and all female 
AF patients with a CHA2DS2-VASc score ≥3.
I A
OAC should be considered in male AF patients with a CHA2DS2-VASc score of 1, and female 
AF patients with a CHA2DS2-VASc score of 2 considering individual characteristics and 
patient preferences.
IIa B
In male or female AF patients without additional stroke risk factors (i.e., CHA2DS2-VASc score 
of 0 in males or 1 in females), anticoagulant or antiplatelet therapy is not recommended for 
stroke prevention.
III 
(harm)
B
In patients with one episode of AF, then stroke prevention with same principles should be 
recommended. 
IIa B
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended in AF patients with 
moderate-to-severe mitral stenosis or mechanical heart valves.
I B
When OAC is initiated in a patient with AF who is eligible for a NOAC, a NOAC is 
recommended in preference to a vitamin K antagonist.
I A
When patients are treated with a vitamin K antagonist, TTR should be kept as high as possible 
(ideally aiming for TTR >65–70%) and be closely monitored.
I A
Bleeding risk assessment should be performed for all patients with AF at every patient 
contact and should initially focus on potentially modifiable bleeding risk factors.
I B
The HAS-BLED score is recommended to address modifiable bleeding risk factors in all AF 
patients. Those potentially at high risk (HAS-BLED score ≥3) warrant more frequent and 
regular reviews or follow-up.
I A
In patients on vitamin K antagonists with consistently low time in INR therapeutic range (e.g., 
TTR <65%), we recommend considering interventions to improve TTR or switching to NOACs.
I A
LEFT ATRIAL APPENDAGE OCCLUSION AND EXCLUSION
Left atrial appendage occlusion devices
Transcatheter left atrial appendage (LAA) occlusion or percutaneous LAA ligation has been 
performed since LAA was proven to be the major source of thrombus formation in patients 
with non-valvular AF. Two RCTs (PROTECT AF and PREVAIL) have directly compared 
the LAA occlusion using a Watchman device® with vitamin K antagonist, and these data 
suggested that LAA occlusion was non-inferior to vitamin K antagonist for the prevention 
of stroke in AF patients with a moderate stroke risk.160-163) Recently published longer-term 
follow-ups of RCTs have demonstrated that the LAA occlusion might reduce the risk of 
thromboembolic stroke compared with vitamin K antagonist.164) A high implantation 
success rate (98%) with an acceptable procedure-related complication rate of 4% at 30 
days was reported in a large recent European registry.165)166) However, these data were in 
contrast with the analyses from insurance databases and systematic reviews that claimed 
higher serious complications related with the implantation procedure, possibly identifying 
a certain degree of reporting bias. There is also uncertainty how a LAA occlusion would 
compare against a NOAC. Therefore, the Korean AF guideline recommends that AF patients 
with contraindications for long-term OAC therapy, a recurrent thromboembolic event, or a 
high risk of stroke despite OAC therapy may be considered to have LAA occlusion for stroke 
prevention purposes (class IIb).
Left atrial appendage occlusion or exclusion
Surgical LAA occlusion or exclusion in conjunction with cardiac surgery has been performed 
with multiple techniques for many decades. The feasibility and safety of surgical LAA 
occlusion/exclusion were proven in various observational studies.167) However, limited 
controlled trial data have been published. The role of concomitant AF surgery and LAA 
occlusion has been evaluated and reported in an RCT in 2015 without showing a clear benefit 
of LAA exclusion for stroke prevention in the subgroup undergoing AF surgery. A large RCT is 
currently underway.168) Therefore, the Korean AF guideline recommends that patients with AF 
undergoing cardiac surgery may benefit from surgical occlusion or the exclusion of LAA for 
stroke prevention (class IIb). Patients undergoing thoracoscopic AF surgery may benefit from 
surgical occlusion or the exclusion of LAA for stroke prevention (class IIb).
RATE CONTROL
Heart rate control is a substantial part of the treatment of patients with AF despite the 
remarkable advancement of pharmacologic and non-pharmacologic rhythm control 
management. An adequately and appropriately controlled ventricular rate can reduce 
or eliminate symptoms, improve hemodynamics, and prevent tachycardia-induced 
cardiomyopathy.
Rate control can be achieved with beta-blockers, non-dihydropyridine calcium channel 
blockers, digoxin, or combination therapy. Certain antiarrhythmic agents including 
amiodarone and sotalol also have rate-controlling effects, but they should be reserved for 
patients requiring rhythm control therapy. When considering which drug to use, clinicians 
should consider the patient's symptoms, hemodynamic status, presence of HF, and 
precipitating factors for AF. Medications for acute and long-term rate control are presented 
in Table 7.
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Acute rate control
In patients with new-onset AF, heart rate control is often needed to control symptoms. Clinicians 
should identify causes of increased heart rate, such as infection, anemia, and thyrotoxicosis. 
Beta-blockers and non-dihydropyridine calcium channel blockers (diltiazem/verapamil) 
are preferred for acute rate control because of their rapid action and effectiveness at high 
sympathetic tone.169-175) Lenient rate control (heart rate <110/min) is sufficient in most cases.
In patients with congestive HF or left ventricular dysfunction, beta-blockers, digoxin, or 
their combination should be used because diltiazem and verapamil have negative inotropic 
effects in those with an LVEF <40%.176)177) In patients with hemodynamic instability or severely 
reduced ejection fraction (EF), intravenous amiodarone would be an option.178)179) Urgent 
electrical cardioversion should be considered in hemodynamically unstable patients despite 
thromboembolic risk unless they are first anticoagulated (Figure 11).
Long-term rate control
Beta-blockers are most commonly used to achieve long-term rate control, followed by non-
dihydropyridine calcium channel blockers (diltiazem/verapamil), digoxin, and amiodarone. 
Physicians should evaluate the patient's comorbidities, such as HF, asthma, or COPD, to 
ensure appropriate drug selection.32)
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Table 7. Rate control therapy in patients with AF25)
Drug Acute rate control (IV) Long-term rate control (PO) Adverse effect Comments
Beta-blockers
Bisoprolol Not available 1.25–10 mg q.d. or split Bradycardia, AV block, and 
hypotension.
Bronchospasm is rare. In cases 
of asthma, recommend beta-1 
selective agents. Contra-indicated 
in acute HF and a history of severe 
bronchospasm.
Carvedilol Not available 3.125–25 mg b.i.d. Lethargy, headache, peripheral 
edema, upper respiratory tract 
symptoms, gastrointestinal upset, 
and dizziness.
8–64 mg q.d. (ER)
Metoprolol Not available 12.5–100 mg b.i.d.
25–200 mg q.d. (ER)
Nebivolol Not available 1.25–10 mg q.d. or split
Esmolol 500 mcg/kg IV bolus over 1 
minutes, then 50–250 mcg/kg/min
Calcium-channel blockers
Diltiazem 0.25 mg/kg IV bolus over 2 
minutes, then 5–15 mg/h
60–120 mg t.i.d. Bradycardia, AV block, and 
hypotension.
Use with caution in combination 
with beta-blockers. Reduce dose 
with hepatic impairment and 
start with smaller dose in renal 
impairment. Contra-indicated in left 
ventricular failure with pulmonary 
congestion or LVEF <40%.
90–360 mg q.d. (ER) Dizziness, malaise, lethargy, 
headache, hot flushes, 
gastrointestinal upset, and edema.
Verapamil 0.075–0.15 mg/kg IV bolus over 
2 minutes, then 5 mcg/kg/min
40–120 mg t.i.d.
120–480 mg q.d. (ER)
Cardiac glycosides
Digoxin 0.25 mg IV with repeated dosing 
to a maximum of 0.75–1.5 mg 
over 24 hours
0.0625–0.25 mg q.d. Gastrointestinal upset, dizziness, 
blurred vision, headache, and 
rash. In toxic states (serum 
levels >2 ng/mL), digoxin is 
proarrhythmic and can aggravate 
HF, particularly with coexistent 
hypokalemia.
High plasma levels associated with 
increased risk of death. Check renal 
function before starting and adapt 
dose in patients with CKD. Contra-
indicated in patients with accessory 
pathways, ventricular tachycardia 
and hypertrophic cardiomyopathy 
with outflow tract obstruction.
Specific indications
Amiodarone 300 mg IV over 1 hour, then 
10–50 mg/hr over 24 hours 
(preferably via central venous 
catheter).
100–200 mg q.d. Hypotension, bradycardia, 
nausea, QT prolongation, 
pulmonary toxicity, skin 
discoloration, thyroid dysfunction, 
corneal deposits and cutaneous 
reaction with extravasation.
Suggested as adjunctive therapy 
in patients where heart rate 
control cannot be achieved using 
combination therapy.
AF = atrial fibrillation; AV = atrioventricular; b.i.d. = twice a day or twice daily; CKD = chronic kidney disease; ER = extended release; HF = heart failure; IV = intravenous; 
LVEF = left ventricular ejection fraction; PO = per os; q.d. = once a day or once daily; t.i.d. = 3 times a day.
In patients with left ventricular dysfunction (EF <40%), beta-blockers, digoxin. or their 
combination are preferred.116) However, beta-blockers should be avoided in patients with 
asthma or COPD. Beta-blockers help rate control but may not have prognostic benefit in HF.73) 
Lenient rate control (heart rate <110/min) is usually acceptable regardless of HF status, but 
stricter rate control is required if symptoms remain uncontrolled (Figure 11).180)
Atrioventricular (AV) nodal ablation consisting of permanent pacemaker implantation could 
be an option in selected patients with a rapid ventricular rate refractory to medical therapy. 
However, AV nodal ablation is usually reserved for the elderly because of their life-long 
pacemaker dependency.
Recommendations for rate control in patients with AF
RHYTHM CONTROL
The purpose of rhythm control management is to improve hemodynamic instability and 
AF-related symptoms for restoring and maintaining sinus rhythm.181) The restoration and 
maintenance of sinus rhythm after AAD treatment are more effective than those after 
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Recommendations Class Level
Beta-blockers, digoxin, diltiazem, or verapamil are recommended to control heart rate in AF 
patients with LVEF ≥40%.
I B
Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with 
LVEF <40%.
I B
Combination therapy comprising different rate controlling agents should be considered if a 
single agent does not achieve the necessary heart rate target.
IIa C
In patients with hemodynamic instability or severely depressed LVEF, amiodarone may be 
considered for acute control of heart rate.
IIb B
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), 
antiarrhythmic drugs (AADs) should not routinely be used for rate control.
III 
(harm)
A
A resting heart rate of <110 bpm (i.e. lenient rate control) should be considered as the initial 
heart rate target for rate control therapy.
IIa B
Rhythm rather than rate control strategies should be considered as the preferred 
management in preexcited AF and AF during pregnancy.
IIa C
AV node ablation should be considered to control heart rate in patients unresponsive or 
intolerant to intensive rate and rhythm control therapy, accepting that these patients will 
become pacemaker dependent.
IIa B
Heart rate control of AF
LVEF <40% or
heart failure
β–blocker
LVEF ≥40%
Add digoxin
Diltiazem, verapamil
or β–blocker
Add diltiazem, verapamil
or β–blockerAdd digoxin
Digoxin
Figure 11. AF rate control management. 
AF = atrial fibrillation; LVEF = left ventricular ejection fraction.
placebo treatment.3)182-184) However, it remains inconclusive whether superior rhythm control 
management improves prognosis in anticoagulated patients with AF.181)182)185-190) Additional 
invasive ablation therapy has been developed for and applied in medically refractory AF 
patients,191-193) and prospective large-scale trials (CODE-AF, EAST-AFNET, and CABANA) 
attributed quality of life and prognosis improvements to the beneficial effect of rhythm 
control strategies in patients with AF.194-196)
Acute rhythm control strategy
Electrical direct current cardioversion is the only rapid and effective procedure to restore 
sinus rhythm in hemodynamically unstable AF patients.197-199) Electrical cardioversion was 
safely conducted in sedated or anesthetized AF patients with intravenous midazolam or 
propofol; when used, vital signs, especially O2 saturation, should be monitored.200) During 
the post-cardioversion period, the skin to which the patch is attached and serial ECG should 
be monitored for burns or severe bradycardia.197)198)
Pretreatment with flecainide,183) propafenone,201) amiodarone,202)203) and sotalol202) (not 
beta-blocker, verapamil,204-206) or digoxin207)208)) could improve the efficacy of restoration 
and maintenance of sinus rhythm during the post-cardioversion period. AADs for 
pharmacological cardioversion are presented in Table 8. Proper anticoagulation is 
needed in AF patients prior to electrical cardioversion209-212) because anticoagulation 
dramatically reduced the risk of embolic stroke.213)214) AF patients planned to undergo 
electrical cardioversion should be anticoagulated from 3 weeks before to 4 weeks after 
unless permanent anticoagulation is indicated. A recent NOAC trial demonstrated the 
efficacy of preventing the occurrence of embolic stroke in AF patients subjected to electrical 
cardioversion.
A meta-analysis demonstrated that AADs could also efficiently restore and maintain sinus 
rhythm as rhythm control management.181)215-225) In AF patients with stable hemodynamic status, 
prescription AADs could be the main option (easily available) in general practice without 
sedation or starvation during pretreatment compared with electrical cardioversion. Flecainide 
and propafenone are the most common AADs for acute rhythm management,222-227) but they are 
relatively contraindicated in AF patients without structural heart disease. Amiodarone could 
be prescribed to AF patients with structural heart disease and reduce the heart by >10–12 beats 
per minute within intravenous infusion after 8–12 hours.216) Both amiodarone and flecainide are 
more efficient at restoring sinus rhythm than sotalol.220)221)228)229) A single oral dose of flecainide 
200–300 mg or propafenone 450–600 mg could be taken to control paroxysmal AF-related 
symptoms and restore sinus rhythm out of the hospital in experienced AF patients as confirmed 
in previous hospitalization (Figure 12A).230)231)
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Table 8. AADs for pharmacological cardioversion25)
Drug Route Dosage Risks
Amiodarone Oral Oral 600–800 mg daily in divided doses to a total load of 
up to 10 g, then 200 mg q.d. as maintenance
Gastrointestinal upset, constipation, bradycardia/AV 
block, hypotension, QT prolongation, torsades de pointes 
(rare), phlebitis (IV), increased INRIV 150 mg over 10 minutes, then 1 mg/min for 6 hours, then 
0.5 mg/min for 18 hours or change to oral dosing
Flecainide Oral 200–300 mg Atrial flutter with 1:1 AV conduction, ventricular 
proarrhythmia, hypotension
Propafenone Oral 450–600 mg Atrial flutter with 1:1 AV conduction, ventricular 
proarrhythmia, hypotension
AAD = antiarrhythmic drug; AV = atrioventricular; INR = international normalized ratio; IV = intravenous; q.d. = once a day or once daily.
Long-term rhythm control strategy
Physician preference and the improvement of AF-related symptoms, drug compliance, 
pro-arrhythmic side effects, and extra-cardiac toxicities should be considered in long-term 
rhythm control management. AADs for the maintenance of sinus rhythm are presented in 
Table 9. In addition, lifestyle modifications and well-controlled cardiovascular disease could 
be additionally beneficial for preventing AF recurrence and maintaining sinus rhythm in 
patients treated with AADs during long-term rhythm control management.232)
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Acute new-onset AF rhythm control management
Electrical
cardioversion
Amiodarone
Sotalol Amiodarone
Flecainide
Propafenone
Pill in
the pocket
Unstable hemodynamic status Stable hemodynamic status
Physician preference
patient compliance
Selection of antiarrhythmic drug
Left ventricular
dysfunction
Ischemic heart
disease
No structural
heart disease
A
Long term AF rhythm control management
Sotalol
Dronedarone
Amiodarone
Flecainide
Pilsicanide
Propafenone
Sotalol
Dronedarone
Amiodarone Amiodarone
No or minimal structural heart disease Structural heart disease
Left ventricular
dysfunction
Ischemic heart
disease
B
Figure 12. AF rhythm control management. (A) acute onset AF and (B) long-term AF. 
AF = atrial fibrillation.
AAD safety must be considered in terms of pro-arrhythmic side effects and extra-cardiac 
toxicities. Flecainide, propafenone, and pilsicainide are indicated to control rhythm in AF 
patients without structural heart disease but are contraindicated in AF patients with ischemic 
heart disease or with left ventricular dysfunction due to poor prognosis.233)234) Extra-cardiac 
toxicity is rarely reported.235)236) Flecainide, propafenone, and pilsicainide should be prescribed 
with an AV nodal blocker for the prevention of use dependency (increased ventricular rate 
in atrial flutter).237) Propafenone has a beta-blocker effect and CYP2D2 as a substrate (7% of 
the general population has no CYP2D2). In a recent meta-analysis, class IC AAD use was not 
significantly correlated with all-cause mortality compared with class IA AAD and class III 
sotalol uses.184) Class IC AADs also significantly reduced the recurrence of AF and had efficacy 
similar to dronedarone and sotalol but inferior to amiodarone (Figure 12B).238)239)
Amiodarone can be prescribed in patients with left ventricular dysfunction.182)240) QT interval 
and U wave should be monitored to prevent torsade de pointes.241) In particular, long-
term amiodarone therapy may have extra-cardiac toxicity in the liver, thyroid, lung, skin, 
and cornea. Therefore, amiodarone should be replaced by an alternative AAD if any side 
effects or toxicities appear during long-term therapy.242) Dronedarone reduces the heart 
rate, maintains sinus rhythm, and reduces cardiovascular mortality and hospitalization in 
paroxysmal or persistent AF patients.243)244) However, dronedarone increased the mortality 
rate in decompensated HF.245)246) Sotalol showed inferior efficacy to amiodarone221) and 
similar efficacy to propafenone for maintaining sinus rhythm.247) Sotalol could effectively 
suppress the re-entry mechanism. Sotalol may be the first choice for long-term rhythm 
control management in AF patients with ischemic heart disease. However, sotalol is prone 
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Table 9. Oral AADs used to maintain sinus rhythm in patients with AF25) 
Drug Dose Contraindications and precautions Warning signs warranting discontinuation
Amiodarone 400–600 mg daily in divided 
doses for 2–4 weeks; 
maintenance typically 
100–200 mg q.d.
Caution: SA or AV node dysfunction, infranodal conduction 
disease, prolonged QT interval, liver disease, lung disease
QT prolongation >500 ms
Inhibits most CYPs and P-glycoprotein: increases warfarin, 
statins, and digoxin concentration
Dronedarone 400 mg b.i.d. Contraindication: NYHA class III or IV HF, permanent AF, 
concomitant therapy with QT-prolonging drugs or powerful 
CYP3A4 inhibitors (e.g., verapamil, diltiazem, azole antifungal 
agents), CrCl <30 mL/min.
QT prolongation >500 ms
Caution: liver disease inhibits CYP3A, CYP2D6, P-glycoprotein: 
increases concentration of digitalis,  
beta-blockers, and of some statins.
Flecainide 50–200 mg b.i.d.  
(usually 50–100 mg b.i.d.)
Contraindication: CAD, HF, CrCl <50 mL/min QRS duration increases  
>25% above baselineCaution: SA or AV node dysfunction, infranodal conduction 
disease, atrial flutter, liver disease.
CYP2D6 inhibitors (e.g., quinidine, fluoxetine, tricyclics) 
increase plasma concentration.
Pilsicainide 50 mg t.i.d. Contraindicated: IHD, reduced LVEF. QRS duration increases  
>25% above baselineCaution: SA or AV node dysfunction, infranodal conduction 
disease, atrial flutter, renal impairment
Propafenone Immediate release:  
150–300 mg t.i.d.
Contraindication: IHD, reduced LVEF QRS duration increases  
>25% above baselineCaution: SA or AV node dysfunction, infranodal conduction 
disease, atrial flutter, liver disease, renal impairment, asthma
Extended release:  
225–425 mg b.i.d.  
(usually 225–325 mg b.i.d.)
CYP2D6 inhibitors (e.g. quinidine, fluoxetine, tricyclics) 
increase plasma concentration
Increases concentration of digitalis and warfarin
Sotalol 40–160 mg b.i.d. Contraindication: HF, significant LV hypertrophy,  
prolonged QT interval, hypokalemia, hypomagnesemia, 
asthma, CrCl <50 mL/min
QT interval >500 ms,  
QT prolongation by  
>60 ms upon therapy initiation
AAD = antiarrhythmic drug; AF = atrial fibrillation; AV = atrioventricular; b.i.d. = twice a day or twice daily; CAD = coronary artery disease; CrCl, creatinine 
clearance; CYP2D6 = cytochrome P450 2D6; CYP3A4 = cytochrome P450 3A4; HF = heart failure; IHD = ischemic heart disease; LVEF = left ventricular ejection 
fraction; NYHA = New York Heart Association; q.d. = once a day or once daily; SA = sinoatrial.
to inducing QT prolongation, and caution is needed in females, renal impairment and if left 
ventricular hypertrophy is present.238)
Recommendations for rhythm control strategies in patients with AF
Anticoagulation in patients who undergo cardioversion
The periprocedural risk of thromboembolic events during cardioversion can be substantially 
reduced by adequate anticoagulation.213) In patients with AF or an atrial flutter ≥48 hours or 
with an unknown duration, OAC with vitamin K antagonist (INR, 2.0–3.0) is recommended 
for at least 3 weeks before electrical or pharmacological cardioversion and 4 weeks afterward 
regardless of CHA2DS2-VASc score.3) If early cardioversion is attempted, TEE should be 
performed to exclude the presence of left atrial thrombus.248) After 4 weeks, long-term 
anticoagulation is decided based on each patient's risk of stroke using CHA2DS2-VASc 
score. Patients with a CHA2DS2-VASc score ≥2 require long-term use of OAC irrespective 
of the cardioversion results. Subgroup analyses of phase 3 clinical trials249-251) and recent 
prospective RCTs of rivaroxaban,252) edoxaban,253) and apixaban254) have demonstrated 
that electrical cardioversion in patients treated with a NOAC for ≥3 weeks had similar 
periprocedural thromboembolic and bleeding risks to those treated with warfarin. Therefore, 
anticoagulation using NOAC can be an alternative to vitamin K antagonist in patients who 
undergo cardioversion. Because routine coagulation tests do not accurately measure the 
anticoagulation effects of NOACs, if patient adherence to the NOAC regimen is uncertain, 
TEE can be performed prior to cardioversion.255) No RCTs have compared anticoagulation 
strategies in patients with AF or an atrial flutter ≤48 hours. It is common practice to perform 
cardioversion after a single dose of unfractionated heparin (UFH) or low molecular weight 
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Recommendations Class Level
Rhythm control therapy is indicated for symptom improvement in patients with AF. I B
Management of cardiovascular risk factors and avoidance of AF triggers should be pursued 
in patients on rhythm control therapy to facilitate maintenance of sinus rhythm.
IIa B
With the exception of AF associated with hemodynamic instability, the choice between 
electrical and pharmacological cardioversion should be guided by patient and physician 
preferences.
IIa C
The choice of AAD needs to be carefully evaluated, taking into account the presence of 
comorbidities, cardiovascular risk and potential for serious proarrhythmia, extracardiac 
toxic effects, patient preferences, and symptom burden.
I A
Dronedarone, flecainide, propafenone, or sotalol are recommended for prevention of 
recurrent symptomatic AF in patients with normal left ventricular function and without 
pathological left ventricular hypertrophy.
I A
Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with 
stable CAD, and without HF.
I A
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with HF. I A
Amiodarone is more effective in preventing AF recurrences than other AAD, but extracardiac 
toxic effects are common and increase with time. For this reason, other AAD should be 
considered first.
IIa C
Patients on AAD therapy should be periodically evaluated to confirm their eligibility for 
treatment.
IIa C
ECG recording during the initiation of AAD therapy should be considered to monitor heart 
rate, detect QRS and QT interval prolongation, and the occurrence of AV block.
IIa B
AAD therapy is not recommended in patients with prolonged QT interval (>0.5 seconds) or 
those with significant sinoatrial node disease or AV node dysfunction who do not have a 
functioning permanent pacemaker.
III 
(harm)
C
Adding atrial-based bradycardia pacing to drug treatment that induces or exacerbates 
sinus node dysfunction should be considered to allow continuation of AAD therapy in 
patients in whom AF ablation is declined or not indicated.
IIa B
Continuation of AAD therapy beyond the blanking period after AF ablation should be 
considered to maintain sinus rhythm when recurrences seem likely.
IIa B
heparin (LMWH) without TEE. Although data are limited, it is reasonable to administer a 
single dose of NOAC ≥4 hours before cardioversion instead of UFH or LMWH. Importantly, 
TEE or anticoagulation ≥3 weeks before cardioversion can be considered in patients with a 
high stroke risk or an AF duration ≤48 hours.
Recommendations for stroke prevention in patients undergoing cardioversion
ANTICOAGULATION IN SPECIFIC CONDITIONS
Atrial fibrillation patients undergoing percutaneous coronary intervention
Antithrombotic regimen
An estimated 5–15% of AF patients may undergo PCI in the future.3) However, it is very 
challenging to choose optimal antithrombotic regimens for AF patients treated with 
PCI.256) Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel) is 
essential for patients treated with PCI to prevent stent thrombosis.257) On the other hand, 
OAC is imperative to preventing stroke in AF patients.258) Thus, theoretically, triple therapy, 
combining all drugs including DAPT and OAC, may be a reasonable choice as an initial 
antithrombotic regimen. However, prolonged triple therapy has been associated with an 
increased risk of bleeding and even mortality.259)260) In a large Korean observational study, 
triple therapy with aspirin, clopidogrel, and warfarin was associated with a 4.5-fold increased 
risk of major bleeding compared to DAPT.261)
Recent well-designed RCTs suggested dual therapy with a single antiplatelet agent and an 
OAC might be safer and show similar efficacy to triple therapy for preventing ischemic/
thromboembolic events.259)262-264) Dual therapy with clopidogrel and NOAC was suggested 
to be a safe initial alternative regimen to triple therapy.262)263) However, in patients with high 
ischemic event risk, short-term triple therapy still seems warranted.3) Thus, we recommend 
the following (Figure 13). First, as initial antithrombotic treatment, triple therapy should be 
used for as short a duration as possible unless patients are at high risk of ischemic events. 
Second, dual therapy should be continued after the cessation of the triple therapy until 12 
months after PCI. Third, dual therapy with clopidogrel and NOAC could be considered as 
an alternative initial antithrombotic regimen in patients with a high risk of bleeding (e.g. 
HAS-BLED ≥3). Fourth, monotherapy with OAC should be considered 12 months after PCI. 
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Recommendations Class Level
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum 
of 3 weeks before cardioversion.
I B
TEE is recommended to exclude cardiac thrombus as an alternative to preprocedural 
anticoagulation when early cardioversion is planned.
I B
In patients at risk for stroke, anticoagulant therapy should be continued long-term after 
cardioversion according to the long-term anticoagulation recommendations, irrespective 
of the method of cardioversion or the apparent maintenance of sinus rhythm. In patients 
without stroke risk factors, anticoagulation is recommended for 4 weeks after cardioversion.
I B
In patients where thrombus is identified on TEE, effective anticoagulation is recommended for 
at least 3 weeks.
I C
Anticoagulation with heparin or a NOAC should be initiated as soon as possible before every 
cardioversion of AF or atrial flutter.
IIa B
Early cardioversion can be performed without TEE in patients with a definite duration of AF 
<48 hours.
IIa B
In patients where thrombus is identified on TEE, effective anticoagulation is recommended for 
at least 3 weeks.
IIa B
Meanwhile, the safety of potent P2Y12 inhibitors (prasugrel, ticagrelor) has not been well 
evaluated in this population. Clopidogrel is the first recommended P2Y12 inhibitor. We 
discuss the evidence of dual therapy and monotherapy below.
Dual therapy with clopidogrel and warfarin
In an RCT (WOEST trial), dual therapy with clopidogrel and warfarin reduced the bleeding 
risk by 64% and adverse cardiac events by 40% compared with triple therapy with aspirin, 
clopidogrel, and warfarin.259) Although this study was underpowered to compare ischemic/
thromboembolic events, it has great implications for demonstrating the safety of dual 
therapy with clopidogrel and warfarin compared to that of triple therapy.
Dual therapy with clopidogrel and non-vitamin K oral anticoagulants
The efficacy and safety of dual therapy with clopidogrel and NOAC have been demonstrated 
in RCTs. In the PIONEER AF-PCI trial, dual therapy with a fixed dose of rivaroxaban 15 mg 
and a P2Y12 inhibitor (mostly clopidogrel) was compared with triple therapies with very-
low-dose rivaroxaban (2.5 mg b.i.d.) or warfarin.263) In that study, the two rivaroxaban arms 
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A. Balanced thrombotic/
bleeding risk
B. High bleeding risk/
low thrombotic risk
C. High thrombotic risk/
low bleeding risk
O Oral anticoagulant withVKA (TTR>70%) or NOAC A Aspirin C Clopidogrel
1 months 3 months 6 months 12 months
Beyond
12 months
C
A
O
C
A
O CO
Triple theraphy
up to 6 months
if possible
Dual
therapy
up to
12 months
CO
Dual
therapy
up to
12 months
CO
Dual therapy
up to 12 months
O
OAC alone
Triple
theraphy
up to
3 months
if possible
Figure 13. Suggested algorithm for antithrombotic therapy in patients undergoing PCI. 
NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; PCI = percutaneous coronary 
intervention; TTR = time in therapeutic range.
reduced the risk of clinically significant bleeding compared with triple therapy with warfarin, 
while the ischemic/thrombotic events were comparable. The results should be interpreted 
carefully. The trial design is complex (DAPT duration varied) and underpowered for the 
comparison of the ischemic events. Rivaroxaban 2.5 mg has not been evaluated for stroke 
prevention in AF patients.
The RE-DUAL PCI trial compared dual therapy with two doses of dabigatran (110 or 150 mg 
b.i.d.) combined with a P2Y12 inhibitor (clopidogrel in 88%, ticagrelor in 12%) and triple 
therapy consisting of aspirin, a P2Y12 inhibitor (clopidogrel in 92%, ticagrelor in 8%), and 
warfarin.262) The dabigatran arms were associated with a reduced risk of major or clinically 
relevant nonmajor bleeding (dabigatran 110 mg: HR, 0.52; dabigatran 150 mg: HR, 0.72) 
compared to triple therapy with warfarin, while the risk of ischemic/thromboembolic events 
was comparable. This trial was also underpowered to compare the individual ischemic/
thromboembolic events, although as an adequately powered secondary efficacy composite 
outcome, the combined dabigatran arms were no significantly different to the warfarin-
based arm.264) Both used dosages of dabigatran that have been proven to prevent stroke in AF 
patients.265)
The AUGUSTUS and ENTRUST-AF trials are the ongoing RCTs of apixaban and edoxaban, 
respectively.266)267) The AUGUSTUS trial in particular will present the efficacy and safety of 
many different regimens of antithrombotic therapy including triple therapy with on-label 
dosages of NOAC.
Monotherapy with oral anticoagulation
In a nationwide observational study of 8,700 AF patients with a history of PCI ≥1 year prior, 
the addition of the antiplatelet agent to warfarin was not associated with a reduced risk of 
ischemic/thromboembolic events but significantly increased bleeding risk.268) The efficacy 
and safety of NOAC monotherapy in patients with stable coronary artery disease has not been 
well evaluated. However, global guidelines recommend the use of OAC monotherapy in AF 
patients with stable coronary artery disease.3)255)269)
Anticoagulation in patients who undergo catheter ablation of atrial 
fibrillation
Since catheter ablation of AF carries a risk of periprocedural thromboembolic complications, 
anticoagulation is indicated before, during, and after the procedure irrespective of the 
patient's CHA2DS2-VASc score. AF ablation under uninterrupted vitamin K antagonist use 
is recommended based on previous studies showing that this strategy was associated with 
better safety and efficacy outcomes.270) Meta-analysis or registry data on periprocedural 
anticoagulation using dabigatran,271) apixaban,272) rivaroxaban,273) and edoxaban274) 
demonstrated similar thromboembolic and bleeding events compared with uninterrupted 
vitamin K antagonist. In addition, recent RCTs with rivaroxaban,275) dabigatran,276) and 
apixaban277) also showed that patients on uninterrupted NOACs had similar or even better 
major bleeding rates than those on vitamin K antagonist. Therefore, anticoagulation 
with NOAC can be an alternative to vitamin K antagonists in patients who undergo 
catheter ablation of AF. During the ablation, the intravenous administration of heparin is 
recommended to maintain a target activated clotting time ≥300 seconds.270) NOACs can 
be re-administered 3–5 hours after the procedure once adequate hemostasis is achieved. 
Anticoagulation should be continued for at least 2 months after ablation regardless of the 
patient's stroke risk or procedure results due to a thrombogenic state following ablation. 
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After 2 months, long-term anticoagulation should be decided based on each individual 
patient's risk of stroke independent of the procedure's success.
Anticoagulation therapy and renal function
Patients with AF and moderate to severe renal dysfunction are at an increased risk of 
simultaneous ischemic stroke and major bleeding.278-281) Therefore, the use of OACs in AF 
patients with renal dysfunction is troublesome. In AF patients with moderate to severe renal 
dysfunction and a CHA2DS2-VASc score ≥2, the use of OACs was approved as beneficial for 
lowering the event rate of ischemic stroke despite the mildly increased risk of bleeding.282) 
In a meta-analysis, NOACs were better than warfarin for reducing the risk of stroke/
systemic embolism as well as major bleeding in AF patients with mild to moderate renal 
dysfunction.283)284) During NOAC use, renal function should be monitored carefully.285)
In patients with moderate renal dysfunction, NOAC dose should be reduced. Dabigatran 
should be reduced to 110 mg b.i.d. in patients with creatinine clearance of 30–50 mL/min.265) 
Rivaroxaban should be reduced to 15 mg q.d. in patients with creatinine clearance of 15–50 
mL/min.286) Apixaban should be reduced to 2.5 mg b.i.d. in patients with serum creatinine 
≥1.5 mg/dL and age ≥80 years or body weight ≤60 kg.287) Edoxaban should be reduced to 
30 mg q.d. in patients with creatinine clearance of 15–50 mL/min.288) Table 3 shows the 
recommended dose reduction of NOAC in Korea.
In patients with severe renal dysfunction (creatinine clearance <15 mL/min), NOAC use is not 
recommended. OAC use may be inappropriate in patients with renal dysfunction who are on 
dialysis, although the data are weak and often do not consider TTR.289-292) However, if TTR is 
>70%, warfarin may have some benefits even in dialysis patients.293)
However, apixaban has United States Federal Drug Administration (FDA)-approved 
indication for use in hemodialysis patients. Based on data from the apixaban package insert, 
patients with AF may receive full-dose therapy (5 mg b.i.d.) while on hemodialysis as long 
as they are <80 years of age and weigh > 60 kg in the United States. If a patient is on dialysis 
and is >80 years of age or weighs <60 kg, then the dose is reduced to 2.5 mg b.i.d. A recent 
study in end stage renal failure showed no significant differences between anticoagulants 
in the risks of stroke or systemic embolism; however, Apixaban was associated with a 28% 
lower risk of major bleeding than warfarin.294) The results of the current analysis are in 
contradiction to bleeding-related morbidity and mortality attributed to dabigatran and 
rivaroxaban in a previous analysis of hemodialysis patients, suggesting that the increased 
bleeding risk in end-stage kidney disease is not a drug class effect for all DOACs. No 
prospective study has examined OAC therapy in patients with renal transplantation. 
Nonetheless, OAC doses should be adjusted according to the creatinine clearance of the 
donor's kidney.
In patients with a creatinine clearance ≥ 95 mL/min, dabigatran 150 mg b.i.d., rivaroxaban 
20 mg q.d., and apixaban 5 mg b.i.d. are recommended. Edoxaban 60 mg q.d. is not 
recommended according to FDA approval. Recent studies showed that edoxaban was 
effective overall, but low-dose edoxaban had lower relative effectiveness for preventing stroke 
or systemic embolism than with warfarin at higher creatinine clearance levels (>95 mL/min) 
in Korean AF patients.295)296) Similar data was observed for CrCl >95 mL/min with apixaban 
and rivaroxaban, but not dabigatran.293)
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Anticoagulation therapy in elderly patients
Increasing age is a risk factor for simultaneous stroke and major bleeding in patients with AF.297-
299) The elderly population is fragile and prone to falls. Nonetheless, OAC use is recommended 
in elderly AF patients because of the high benefit/risk ratio.300) Recent Asian data showed 
that Among patients with AF ≥90 years of age, warfarin was associated with a lower risk of 
ischemic stroke and positive net clinical benefit. Compared with warfarin, NOACs were 
associated with a lower risk of intracranial haemorrhage. Thus, OACs may still be considered as 
thromboprophylaxis for elderly patients, with NOACs being the more favorable choice.301)302)
All 4 NOACs in the elderly population are approved as beneficial for the risk reduction of 
intracranial bleeding compared with warfarin.265)286-288) In the ARISTOTLE trial, apixaban 
5 mg b.i.d. reduced major bleeding in patients 65–74 years of age and ≥75 years of age.303) 
In the ENGAGE-TIMI trial, edoxaban 60 mg q.d. decreased the risk of major bleeding in 
patients <75 years of age but had similar risks in patients >75 years of age compared with 
warfarin.288) However, dabigatran showed a significant age–treatment interaction in the RELY 
trial. Dabigatran 150 mg b.i.d. reduced major bleeding in patients <75 years of age but an 
increased risk of major bleeding in patients >75 years of age compared with warfarin.265) In 
the ROCKET-AF trial, rivaroxaban demonstrated a similar risk of major bleeding as warfarin 
and no age-treatment interaction.286) However, the J-ROCKET study and many real-world data 
suggested that low-dose rivaroxaban might be safe and effective in elderly Asian AF patients 
with relatively low body weight.145)304)305) Therefore, the Korean AF guideline recommends 
low-dose rivaroxaban (15 mg q.d.) in patients aged ≥80 years.306)
CONCLUSIONS
For AF detection, ECG screening is necessary, especially in stroke survivors and the elderly. 
Integrated AF management, including active patient participation, a multidisciplinary 
approach, and technology use, is recommended from diagnosis to treatment and systematic 
follow-up. Such a holistic approach (the ABC pathway) can improve treatment outcomes, 
by considering lifestyle modifications, OAC, rate control, rhythm control by AADs, catheter 
ablation, and surgical intervention. Patient awareness of the disease, education and 
engagement with management decisions are important.
The Korean versions of separate guidelines for OAC, rate and rhythm control, risk factor 
management, and integrated treatment of AF patients are available in the Korean Journal of Medicine 
(http://ekjm.org/) or the home page of the Korean Heart Rhythm Society (http://k-hrs.org/intro.asp).
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